Effect of bevacizumab combined with"carboplatin+paclitaxel"chemotherapy on immune function and progression free survival in patients with stage ⅢB-Ⅳ ovarian cancer
Objective To investigate the effect of bevacizumab combined with"carboplatin+paclitaxel"chemotherapy on immune function and progression free survival(PFS)in patients with stage ⅢB-Ⅳ ovarian cancer.Methods The clinical data of 65 patients who were diagnosed as suffering from stage ⅢB-Ⅳ ovarian cancer in Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine from January 2020 to October 2022 were retrospectively analyzed.They were divided into the study group(n=33)and control group(n=32)according to different treatment methods.All the 65 patients received surgical treatment.After surgery,the patients in the control group underwent"carboplatin+paclitaxel"chemotherapy after surgery while those in the study group received bevacizumab based on the treatment regimen of the control group.The clinical efficacy was compared between the two groups.Results The differences of the total effective rate,6-month survival rate,12-month survival rate and incidence of adverse reactions were not statistically significant between the two groups(all P>0.05).Compared with those before treatment,the levels of serum carbohydrate antigen 125(CA125),carcinoembryonic antigen(CEA),CD4+and CD4+/CD8+in both groups were decreased after treatment(all P<0.05).The levels of CA125,CEA,CD4+,and CD4+/CD8+in the study group were lower than those in the control((56.44±6.94)U·L-1 vs(87.19±7.36)U·L-1,(6.94±1.36)ng·mL-1 vs(10.91±1.84)ng·mL-1,(30.13±3.57)%vs(32.26±4.71)%,(0.85±0.19)vs(0.96±0.17))(t=17.335,9.914,2.059,2.457,all P<0.05),while the CD8+levels in the study group was higher than that in the control((35.45±3.39)%vs(33.60±3.51)%,t=16.832,P<0.05).The PFS of the study group was significantly longer than that of the control((5.41±1.63)months vs(3.86±1.39)months,t=4.119,P<0.05).Conclusion The application of bevacizumab combined with"carboplatin+paclitaxel"chemotherapy in patients with stage ⅢB-Ⅳ ovarian cancer can effectively improve immune function,promote the efficacy and prolong PFS.
NETL
NSTL
万方数据
